L 373890|CAS 187162-33-0|DC Chemicals

Cas No.:	187162-33-0
Chemical Name:	L 373890
Formula:	C₂₂H₃₀N₆O₄S
M.Wt:	474.58
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC29133	Bivalirudin	Bivalirudin, a peptide anticoagulant,direct thrombin inhibitor for anticoagulation in the setting of invasive cardiology, particularly percutaneous coronary intervention.
DC28998	Heparin sodium salt (MW 15kDa)	Heparin sodium salt (MW 15kDa) (Sodium heparin (MW 15kDa)) is a polymer of Heparin with the molecular weight of 15kDa. Heparin sodium salt is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa.
DC8913	Dabigatran etexilate mesylate	Dabigatran etexilate mesylate (BIBR 1048MS) serves as the orally bioavailable prodrug of the active anticoagulant dabigatran. Following absorption, this precursor compound undergoes enzymatic conversion to release dabigatran - a highly selective, reversible direct thrombin inhibitor (DTI) with exceptional potency (Ki = 4.5 nM).
DC79695	Idrabiotaparinux sodium	Idrabiotaparinux sodium is a derivative of Idraparinux synthesized with biotin. Idraparinux is a polymethylated synthetic pentasaccharide known to interact with the antithrombin III and act as anticoagulant.
DC79689	L 373890	L 373890 is a selective pyridinone acetamide thrombin inhibitor with a Ki of 0.5 nM. L 373890 shows highly selectivity for thrombin over trypsin (Ki of 570 nM), serine proteases plasmin, tPA, activated protein C, plasma kallikrein and chymotrypsin. L 373890 can be used for thrombosis research.
DC79440	AT-1459	AT-1459 is a selective and orally active direct Thrombin inhibitor with a Ki value of 4.9 nM. AT-1459 exhibits excellent antithrombotic activity in both rat models of venous and arterial thrombosis. AT-1459 can be used for research on thrombosis-related diseases.
DC78738	NAPAP	NAPAP is a thrombin inhibitor. It has potent antithrombin activity (Ki: 2.1 nM). NAPAP selectively inhibits thrombin via a rapid binding mechanism, and has weaker inhibitory effects on trypsin, factor Xa, and plasmin. NAPAP can be used in the study of thrombotic diseases (e.g., venous thrombosis, myocardial infarction).
DC77991	Thrombin aptamer sodium	Thrombin aptamer is a 11mer-DNA aptamer that targets thrombin. Thrombin aptamer inhibites thrombin-catalysed fibrin-clot formation in vitro
DC77988	Sulodexide solution	Sulodexide solution is a mixture of glycosaminoglycans that can be administered by injection. It is composed of low molecular weight heparin (80%) and dermatan sulfate (20%). Sulodexide exhibits antithrombotic activity through interaction with antithrombin III (AT III) and heparin cofactor II (HC II), and inhibition of thrombin formation. Sulodexide exhibits profibrinolytic activity through release of tissue plasminogen activator (tPA). Sulodexide exhibits endothelial protective and anti-inflammatory effect, ameliorates chronic venous disease.
DC76886	Heparin	Heparin is a highly sulfated polysaccharide primarily used as an anticoagulant, which works mainly by inhibiting thrombin (FIIa) and/or factor Xa (FXa). It is commonly used to prevent and treat thromboembolic conditions such as deep vein thrombosis and pulmonary embolism. It also plays roles in inflammation, angiogenesis, and growth factor signaling, with potential therapeutic applications in cancer treatment and allergic conditions.